COVID-19 | Boehringer Ingelheim

新冠肺炎 COVID-19

作為一家以研發究導向的公司，我們是對抗 COVID-19 肺炎疫情的集體努力團隊的一部分。百靈佳殷格翰雖不開發人用疫苗；然而，利用我們與眾不同領域的專業知識，與學術研究人員、各式各樣的國際機構和製藥同業......密切合作，我們開展了多項為這一流行病尋找醫療解決方案的努力。

As a research-driven company, we are part of the collective effort in fighting COVID-19. Boehringer Ingelheim does not develop human vaccines; however, drawing from our different areas of expertise we have engaged in a number of activities to find medical solutions to this pandemic, working closely with academic researchers, international institutions and others in the pharma industry.

我們對超過一百萬種化合物的分子庫進行了完整的運算篩選。也針對所有已上市產品的化合物進行測試，希望能為患者找到潛在的治療方法。同時，我們參與了可以中和病毒的 SARS-CoV-2 抗體的研究和開發，以及染疫病人血栓預防的療法開發。

We conducted computational screening of our entire molecule library of more than one million compounds. Existing compounds from our current pipeline and portfolio were also tested as potential treatments for patients. We are involved in the research and development of SARS-CoV-2 antibodies that can neutralize the virus and the development of therapies to prevent blood clots.

了解更多持續對抗新冠肺炎的消息

Learn more about our ongoing engagement in the fight against COVID-19.